AT-1 receptor and phospholipase C are involved in angiotensin III modulation of hypothalamic noradrenergic transmission
- PMID: 11100981
- PMCID: PMC11537518
- DOI: 10.1023/a:1007059010571
AT-1 receptor and phospholipase C are involved in angiotensin III modulation of hypothalamic noradrenergic transmission
Abstract
1. We previously reported that angiotensin III modulates noradrenergic neurotransmission in the hypothalamus of the rat. In the present work we studied the effects of angiotensin III on norepinephrine release and tyrosine hydroxylase activity. We also investigated the receptors and intracellular pathways involved in angiotensin III modulation of noradrenergic transmission. 2. In rat hypothalamic tissue labeled with [3H]norepinephrine 1, 10, and 100 nM and 1 microM losartan (AT1 receptor antagonist) had no effect on basal neuronal norepinephrine release, whereas 10 and 100 nM and 1 microM losartan partially diminished norepinephrine secretion evoked by 25 mM KCl. The AT2 receptor antagonist PD 123319 showed no effect either on basal or evoked norepinephrine release. The increase in both basal and evoked norepinephrine output induced by 1 microM angiotensin III was blocked by 1 microM losartan, but not by 1 microM PD 123319. 3. The phospholipase C inhibitor 5 microM neomicin inhibited the increase in basal and evoked norepinephrine release produced by 1 microM angiotensin III. 4. Tyrosine hydroxylase activity was increased by 1 microM angiotensin III and this effect was blocked by 1 microM LST and 5 microM neomicin, but not by PD 123319. On the other hand, 1 microM angiotensin III enhanced phosphatidyl inositol hydrolysis that was blocked by 1 microM losartan and 5 microM neomicin. PD 123319 (1 microM) did not affect ANG III-induced phosphatidyl inositol hydrolysis enhancement. 5. Our results confirm that angiotensin III acts as a modulator of noradrenergic transmission at the hypothalamic level through the AT1-phospholipase C pathway. This enhancement of hypothalamic noradrenergic activity suggests that angiotensin III may act as a central modulator of several biological processes regulated at this level by catecholamines, such as cardiovascular, endocrine, and autonomic functions as well as water and saline homeostasis.
Similar articles
-
Angiotensin II receptors involved in the enhancement of noradrenergic transmission in the caudal artery of the spontaneously hypertensive rat.Br J Pharmacol. 1996 Nov;119(5):965-75. doi: 10.1111/j.1476-5381.1996.tb15766.x. Br J Pharmacol. 1996. PMID: 8922747 Free PMC article.
-
Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat.Br J Pharmacol. 1996 Nov;119(5):976-84. doi: 10.1111/j.1476-5381.1996.tb15767.x. Br J Pharmacol. 1996. PMID: 8922748 Free PMC article.
-
Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.Biochem Pharmacol. 2013 Sep 1;86(5):656-65. doi: 10.1016/j.bcp.2013.06.025. Epub 2013 Jul 4. Biochem Pharmacol. 2013. PMID: 23831951 Free PMC article.
-
Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus.Hypertension. 2000 Jun;35(6):1248-52. doi: 10.1161/01.hyp.35.6.1248. Hypertension. 2000. PMID: 10856272
-
Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling.Regul Pept. 1997 Oct 31;72(2-3):139-45. doi: 10.1016/s0167-0115(97)01050-1. Regul Pept. 1997. PMID: 9652973 Review.
Cited by
-
Renin-angiotensin system: The underlying mechanisms and promising therapeutical target for depression and anxiety.Front Immunol. 2023 Jan 24;13:1053136. doi: 10.3389/fimmu.2022.1053136. eCollection 2022. Front Immunol. 2023. PMID: 36761172 Free PMC article. Review.
-
Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives.Br J Pharmacol. 2003 May;139(2):191-202. doi: 10.1038/sj.bjp.0705262. Br J Pharmacol. 2003. PMID: 12770924 Free PMC article. Review.
References
-
- Abdelrahman, A., and Pang, C. C. Y. (1992). Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan. Can. J. Physiol. Pharmacol.70:716-719. - PubMed
-
- Blair-West, J. P., Coghlin, J. P., Denton, D. A., Fei, D. T. W., Hardy, K. J., Scoggins, B. A., and Wright, R. D. (1980). A dose-response comparison of the actions of angiotensin II and angiotensin III in sheep. J. Endocrinol.87:409-417. - PubMed
-
- Blair-West, J. R., Coglhlin J. P., Denton D. A., Funder J. W., Scoggins B. A., and Wright E. D. (1971). Effect of the heptapeptide (2-8) and hexapeptide (3-8) fragments of angiotensin II on aldosterone secretion. J. Clin. Endocrinol. Metab.32:575-578. - PubMed
-
- Campbell, W. B., and Pettinger, W. A. (1976). Organ specificity of angiotensin II and desaspartyl angiotensin II in the conscious rat. J. Pharmacol. Exp. Ther.198:450-456. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous